To investigate the unique distribution in plasma of apolipoprotein A-IV (apo A-IV) we have determined, in a series of in vitro and in vivo studies, the redistribution among lipoproteins of
on the basis that it is a major component of lymph chylomicrons in humans and in other species (1) (2) (3) (4) (5) , and that in the rat it is present in moderate amounts in high density lipoprotein (HDL) (2, 3, (6) (7) (8) (9) . Unlike most other apolipoproteins, however, apo A-IV is not a major component of human plasma lipoproteins, and although present in moderate concentrations ofbetween 14 and 30 mg/dl (5, 10), most of the apo A-IV exists in the lipoprotein-deficient fraction (LDF) of plasma (d > 1.21 g/ml). Recent studies in this laboratory have shown, however, that even in the fraction with d > 1.21 g/ml apo A-IV exists in association with lipids and other apolipoproteins in lipoproteinlike species comprising apo A-IV, phospholipid, cholesteryl ester, and triglyceride as well as apo A-I and a third peptide of Mr 59,000 (1 1) . This has raised the possibility that apo A-IV in the LDF of plasma may have functional relationships that are distinct from those of apo A-IV in HDL and chylomicrons.
Apo A-IV concentrations rise in plasma after the ingestion of fat (12) , and we have found elevated levels in patients with chronic renal failure in association with the accumulation of chylomicron remnants (13) . Its presence in high concentration in lymph chylomicrons ofboth humans (5, 12) and experimental animals ( 14) suggests that it may play either a structural or metabolic role, or both, in triglyceride transport. Recent studies have suggested it may also be involved in cholesterol transport since, in rats, the distribution of apo A-IV between HDL and the LDF of plasma is influenced by feeding cholesterol (8) .
The unusual distribution and metabolism of the A-IV apolipoprotein may provide a clue to its function. It is important therefore to determine the manner in which the peptide exchanges or transfers between different human plasma fractions, and in this paper we report studies on the redistribution of apo A-IV in human plasma, in two sets of experiments. Firstly, the distribution of radiolabeled apo A-IV was determined in vitro during incubations with plasma or lymph. Secondly, the distribution of radiolabeled apo A-IV was followed in vivo within plasma over 2 d after infusing labeled apo A-IV to determine the physiological compartmentalization of apo A-IV in plasma.
Methods
Isolation ofapo A-IV. Apo A-IV was isolated from the LDF of plasma and human lymph triglyceride-rich lipoproteins (TRL) as described before (1 1) . Briefly, lipoprotein-deficient plasma was prepared by removing lipoproteins of d < 1.25 g/ml by ultracentrifugation and dialyzed against 0.15 M NaCl containing 1 mM EDTA buffered to pH 7.4 with Trizma base (Sigma Chemical Co., St. Louis, MO) (buffer A).
The dialyzed LDF was mixed with 0.3 vol artificial fat emulsion (Neutralipid; Pharmacia Fine Chemicals, Piscataway, NJ) and incubated at 37°C for 2 h. After centrifugation in a rotor (model SW-41; Beckman Instruments, Inc., Fullerton, CA) for 30 min at 4°C, the supernatant lipid layer was dispersed in buffer A to yield the original volume of Neutralipid and centrifuged twice further to remove unbound plasma protein. Finally, the lipid layer was resuspended in buffer A and delipidated with chloroform, methanol, and ether as described previously (15) .
The delipidated protein was immediately dissolved in 0.1 M Tris HCI, pH 7.5, containing 6 M urea and subjected to chromatography on a column of QAE-Sephadex A-50 (Pharmacia Fine Chemicals). A linear gradient of NaCl was established between 0 and 0.3 M NaCl in 6 M urea and 0.1 M Tris HCI, pH 7.5. The fraction richest in apo A-IV was pooled, dialyzed, and lyophilized. Final purification of apo A-IV was carried out using preparative gel electrophoresis on 10% polyacrylamide gels (in 0.1% sodium dodecyl sulfate [SDS] ) in the presence of fl-mercaptoethanol (3) .
Preparation of antiserum. New Zealand White rabbits (2.5-3 kg)
were immunized with 100 gg of purified LDF apo A-IV. The protein solution was emulsified with an equal volume of Freund's complete adjuvant and injected intradermally into multiple sites on the backs of the rabbits. The injection was repeated intramuscularly three times at intervals of 2-3 wk, and animals were bled 8 d after the last injection. The antisera did not react with pure apo A-I, A-II, B, C-I, C-IT, C-III, or E nor with albumin, but in immunoassay procedures appeared identical to antisera prepared against apo A-IV from lymph TRL. Apo A-IV isolated from LDF and lymph TRL reacted with lines of identity against apo A-IV antiserum in exactly the same manner as native apo A-TV within LDF, TRL, and HDL.
Apo A-IV Sepharose 4B affinity column. Purified apo A-IV from plasma LDF was dissolved and extensively dialyzed against 0.1 M NaHCO3 containing 0.5 M NaCl (pH 8.0). Then apo A-IV was coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals) at pH 8.0, as described by Cuatrecasas (16), using a ratio of 1 mg apo A-IV/ml of activated Sepharose 4B. Finally, apo A-IV Sepharose 4B was equilibrated with 0.1 M borate containing 1.0 M NaCl and 0.1% Tween 20, pH 8.0, and transferred to chromatography columns.
Antiserum to apo A-IV was used for the isolation ofapo A-IV-specific IgG. Antiserum, prepared as described above, was dialyzed against equilibrating buffer and applied to the apo A-IV Sepharose 4B affinity column. Material bound to the column was eluted with 0.2 M glycine/HCI, pH 2.5, and dialyzed against buffer A. The eluate from the column showed a single band on SDS polyacrylamide gel electrophoresis and immunologically reacted only with apo A-IV.
Anti-apo A-IVSepharose 4B column (A-IV immunoaffinity column).
Apo A-IV-specific IgG was dialyzed against 0.1 M K2HPO4 containing 0.5 M NaCI (pH 6.5) and coupled to cyanogen bromide-activated Sepharose 4B as described by Cuatrecasas (16) using a ratio of 2 mg IgG/ ml activated Sepharose 4B. Chromatography was performed on a column of 2.5 X 30 cm. Anti-apo A-IV Sepharose 4B was packed above twice the bed volume of Sephadex G-25 (Medium; Pharmacia Fine Chemicals) in 0.05 M Tris containing 0.5 M NaCl, pH 7.5, to avoid prolonged interaction ofthe desorbing reagent with protein eluted from the column. Then the column was equilibrated with 0.05 M Tris containing 0.5 M NaCl and 0.1% NaN3 at pH 7.5.
Isolation of apo A-IVfrom human lymph TRL. TRL was isolated from the lymph obtained from the chylous pleural effusion of a patient with tuberous sclerosis with lymphangiomyomatosis of the thoracic duct. Centrifugation was carried out, without further adjustment of density in a 45-Ti rotor in the ultracentrifuge (model L 5-65B; Beckman Instruments, Inc.) for 5 h at 4°C. After removal ofthe infranate by aspiration, the gel like creamy supernatant at the top was resuspended in 30 ml of buffer A. The top fraction was recentrifuged for 6 h at 50,000 rpm in a 50-Ti rotor (Beckman Instruments, Inc.). A portion of the lipoprotein was delipidated with chloroform, methanol, and ether as described above. The apolipoprotein moiety was dissolved in the equilibrating buffer (immunoaffinity column buffer), dialyzed against the same buffer for 16 h, and applied to the anti-apo A-IV IgG immunoaffinity column. Application ofthe sample was followed by extensive washing with equilibrating buffer until the absorbance (280 nm) returned to the base line. Material bound to the column was eluted with 6 M guanidine HCI, pH 3.1, and then dialyzed against buffer A. Radioiodination ofapo A-IV. Immunoaffinity-purified apo A-IV from lymph TRL (0.1 mg dissolved in 0.2 ml 4 M borate buffer, pH 8.0) was labeled with 125I by the iodine monochloride technique (17) . Efficiency of labeling was~-.225% and the iodine/protein ratio was <1 g/atom iodine per mol protein. Removal of free 1251 was accomplished by gel filtration through Sephadex G-50 columns (0.7 X 20 cm), equilibrated with buffer A followed by dialysis against the same buffer.
Analytical procedures. Disk gel electrophoresis in 15% polyacrylamide gels containing 0.1% SDS was performed according to the methods described by Weber and Osborn (18) using Tris HCI rather than phosphate buffer.
Isoelectric focusing was performed in polyacrylamide disk gels containing 8 M urea and ampholytes (pH 4-6), essentially as described by Gidez et al. (19) . Amino acid analysis was performed on an analyzer (model 6300; Beckman Instruments, Inc.). Samples were dialyzed against distilled water, lyophilyzed, and hydrolyzed in 6 N HCO at 11 50C for 24 h in evacuated sealed tubes.
To compare the amino acid composition of the major isoforms of apo A-IV, two-dimensional gel electrophoresis was performed as described previously (1 1). After staining and destaining the second dimension slab gels, the corresponding isoforms from four separations were pooled and the proteins electroeluted from the gel slices. The proteins were then precipitated with 9 vol of pure methanol, allowed to stand overnight at -20'C, and the apolipoproteins were then recovered by centrifugation at 2,000 rpm for 5 min at 40C, leaving Coomassie Blue and SDS in the methanol phase. After they were washed once with methanol, the peptides were dried under N2 and hydrolyzed as described above.
In vitro studies
Incubation of23I-apo A-IV with plasma and lymph. The 1251-apo A-IV was mixed with either normal plasma (7 ml), human thoracic lymph (7 ml), or a mixture of lymph (3.5 ml) and normal plasma (3.5 ml) and incubated for 1 h at 370C while being gently shaken. The samples were then applied to a column (2.5 X 90 cm) of Sepharose CL-6B (6% agarose gel; Pharmacia Fine Chemicals) equilibrated with buffer A. The flow rate was 21 ml/h, and fractions of 4.2 ml were collected. The column was operated at 6°C. The tubes were monitored for absorbance at 280 nm and radioassayed to identify '251I-apo A-IV-containing fractions.
In further experiments labeled fractions obtained after gel filtration were reincubated with either plasma or lymph. Briefly, a portion (2 ml) of '251I-apo A-IV lymph TRL and HDL from Sepharose CL-6B columns was mixed with plasma (5 ml) or lymph (5 ml). Similar reincubations were performed with the LDF (pooled from several columns and concentrated to obtain sufficient radioactivity). The mixtures were shaken gently at 37°C for 1 h and applied to a Sepharose CL-6B column in the same manner as described before. Altogether six sets of incubations were carried out as shown in Table II , each experiment having been performed three times.
Measurement of apo A-IV concentration. Apo A-IV concentration was determined by electroimmunoassay as described before (3). The antisera used in this study showed strong, clear rocket-type precipitation zones with pure apo A-IV (used as standards) or when apo A-IV was present in plasma or lipoprotein fractions. The immunoassay was sensitive at concentrations as low as 3 jg/ml.
In vivo studies
Subjects. Five studies were carried out in which labeled apo A-IV in lymph TRL, plasma TRL, HDL, or LDF was injected intravenously. Each preparation was obtained from a separate subject and reinjected into the donor. The various fractions were separated by ultracentrifugation (20) , and the apo A-IV within each fraction was radioiodinated by exchange with purified sterile and pyrogen-free 251I-apo A-IV. Each lipoprotein or LDF was incubated with 3-5 mg labeled apo A-IV (40-70 ,uCi) at 37°C for 1 h and then reisolated in the appropriate density range. Sterility and pyrogenicity were established before administration.
The details of the five subjects are given in Table IV . Briefly, lymph TRL was injected into a normolipidemic woman (no. 1) with a chylothorax, plasma TRL was injected into a man (no. 2) with hyperchylomicronemia (type 5 hyperlipoproteinemia), HDL was injected into a man (no. 3) with mild hypertriglyceridemia, and LDF was injected into a man (no. 4) with combined hyperlipoproteinemia and another (no. 5) with moderate hypertriglyceridemia. Written consent was obtained from each subject.
Distribution ofApolipoprotein A-IV in Human Plasma
In vivo distribution ofapo A-IV. After the labeled preparation was injected, samples of blood were obtained frequently during the first 6 h and less often thereafter for 26-28 h as shown in Figs. 3-7. Normal food intake including fat was allowed. To process large numbers of plasma samples, lipoproteins were separated by ultracentrifugation rather than by gel filtration after preliminary experiments that demonstrated similar findings with the two methods. The ratios of the specific radioactivities of apo A-IV in HDL and in LDF were, respectively, 15 and 13 when the same sample was fractionated by gel filtration or by ultracentrifugation.
Plasma (10 ml) was centrifuged at 40C in the 50-Ti rotor of an ultracentrifuge (Beckman Instruments, Inc.). Plasma TRL comprising both chylomicrons and very low density lipoprotein (VLDL) were removed, and HDL and LDF were sequentially isolated (21) . The fractions were dialyzed and assayed for radioactivity and apo A-IV concentration. Recovery of apo A-IV radioactivity after ultracentrifugation was 83-91%.
The apo A-IV concentration was determined by rocket electroimmunoassay, as described above. Adequate amounts were present in HDL and in LDF only. Specific radioactivity time curves were therefore possible only for those two fractions. Radioactivity associated with TRL apo A-IV was present in sufficient concentration for accurate assay.
Results
Characterization ofisolated apo A-IV. Fig. 1 demonstrates that the apo A-IV, which was subsequently used in the following in vitro incubations, was isolated in pure form from delipidated lymph TRL (Fig. 1 A) , though it comprised several major and minor isoproteins (Fig. 1 B) , which have been characterized in detail and reported elsewhere (1 1). In brief, a similar number of isoproteins were observed in lymph TRL, plasma HDL, or plasma LDF, and all were positively identified as apo A-IV isoproteins by immunoblotting techniques.
Additionally, the amino acid compositions were determined on five isoforms of apo A-IV after they were separated by twodimensional gel electrophoresis. Insufficient amounts ofthe other five minor isoforms were recovered for analysis. As demonstrated in Table I , each isoform analyzed showed a similar amino acid composition that was consistent with the proportions of amino acid residues present in native apo A-IV.
The preparations ofapo A-IV that were isolated as described above and subsequently radioiodinated for use in the redistribution studies showed the physical and chemical characteristics A B In vitro metabolism of apo A-IV. The major aim of the in vitro incubations was to determine the pattern of redistribution of radiolabeled apo A-IV among those plasma or lymph fractions that normally contain apo A-IV, TRL (VLDL and chylomicrons), HDL, and LDF. The series of incubations in which either plasma or lymph was incubated with either pure '25I-apo A-IV or 125I-apo A-IV previously incorporated into TRL, HDL, or LDF are shown in Table II and Figure 2 A-F. The data shown was obtained using apo A-IV derived from lymph TRL, but similar results were obtained using apo A-IV derived from LDF. The Sepharose CL-6B columns were calibrated with lymph chylomicrons, plasma VLDL, LDL, HDL, and albumin to calibrate the volume of elution of each fraction as marked in Fig. 2 . Recoveries of 1251-apo A-IV from the columns were 95.0±+1.9%.
The isolated '25I-apo A-IV associated predominantly with However, under these circumstances more label remained with the fraction with which it had become initially associated. Thus, for example, more '25I-apo A-IV was recovered in HDL when 0 lymph was incubated with HDL-associated '251I-apo A-IV than -f with 251I-apo A-IV alone; however, with both incubations most 0 of the label redistributed to the TRL fraction. The important exception to this was the retention of most of the label with apo A-IV in plasma LDF. When whole plasma was incubated with 'O LDF-associated '251-apo A-IV, only 30% of radioactivity transx E ferred to HDL, but the specific radioactivity of HDL apo A-IV was -15-fold higher than that of LDF apo A-IV, a ratio similar to the one observed when plasma was incubated with "free" radioiodinated apo A-IV.
We also measured the apo A-IV specific radioactivity in TRL, 0 HDL, and LDF after a mixture of lymph and plasma had been a incubated with 1251I-apo A-IV. As shown in Table III (Table III) . The ratio of apo A-IV specific radioactivities in HDL/LDF was 15.3 with uniformly labeled HDL. This dem- 5 onstrates that native apo A-IV was no more freely exchangeable between LDF and HDL than isolated labeled apo A-IV.
In control studies in which 1251-apo A-IV associated with either lymph TRL, plasma HDL, or plasma LDF was incubated in buffer A, the entire label remained in the chromatographed TRL, HDL fraction, and LDF, respectively. disproportionately more '25I-apo A-IV became rapidly associated with HDL than with LDF; (c) the specific radioactivity of apo A-IV was therefore invariably much higher (10-30-fold) in HDL than in LDF; (d) isotopic exchange was attained rapidly with apo A-IV in LDF and appeared slowest for apo A-IV in TRL (VLDL); (e) the specific radioactivity time curves for apo A-IV in HDL and in LDF declined apparently in parallel over the first 48 h, suggesting that the bulk of apo A-IV in LDF did not exchange with that in HDL or at most, very slowly; and (f) the half-life for the decline of the slower, second exponential was of the order of 20-30 h.
Discussion
As pointed out earlier, a physiological role for apo A-IV remains unknown. The peptide becomes associated with lymph TRL during the secretion of chylomicrons (12) but in human plasma is mainly found unassociated with the major lipoproteins (LDF), with <5% of the total present in HDL. This unusual plasma distribution may be the end result of its metabolic fate or representative of its functional role in lipid transport. On the basis of our previous study (1 1) it seems unlikely that apo A-IV in LDF is structurally distinct from that associated with lipoproteins. However, apo A-IV apparently unassociated with lipoproteins in LDF may exist in a unique association with other proteins, lipids, or other unknown components, differing from its state within HDL or chylomicrons (1 1). In this study we have further investigated this possibility by examining the ability of labeled apo A-IV to exchange or transfer between the various lipoprotein or nonlipoprotein compartments of plasma and lymph during in vitro incubations and after in vivo infusions.
In vitro studies. After incubating 1251-apo A-IV with normal plasma, 72% of the label was associated with the HDL fraction and only 14% was not associated with lipoproteins (experiment 1, Table II ). This proportioning of label is quite different from the mass distribution of plasma apo A-IV, in which >90% of the apo A-IV is present in LDF. Specific radioactivity determinations after incubation emphasized the fact that the redistribution of 1251-apo A-IV was not proportional to the distribution of apo A-IV mass since HDL apo A-IV had a 15-fold higher specific radioactivity than that of LDF apo A-IV. When we incubated '25I-apo A-IV with human thoracic lymph (experiment 2) 65% of apo A-IV was recovered in TRL and 13% was associated in LDF; the specific radioactivity of TRL apo A-IV was also 15-fold higher than that of LDF apo A-IV. By contrast, the specific radioactivities of TRL apo A-IV and HDL apo A-IV became similar, indicating that the distribution of 125I-apo A-IV between TRL and HDL was proportional to the distribution of apo A-IV mass between these two fractions, but not between TIME (Hours) Figure 7 . Redistribution of '251-apo A-IV after injection of in vitro labeled 'l25-apo A-IV plasma LDF into a man with moderate hypertriglyceridemia. Top panel shows total radioactivity in VLDL, HDL, and LDF. Bottom panel shows specific radioactivity of apo A-IV in HDL and LDF. When labeled apo A-IV in LDF was incubated with plasma, most labeled apo A-IV remained in LDF (experiment 6), although the specific radioactivity of HDL apo A-IV was also 15-fold higher than that of LDF apo A-IV. This interesting result together with experiment I indicates that most of the unlabeled mass of apo A-IV in LDF is refractive to free exchange with labeled apo A-IV (experiment 1) or to free exchange or transfer with apo A-IV in HDL or TRL. Nevertheless a small fraction ofthe apo A-IV in LDF was exchangeable with these lipoproteins because the labeled apo A-IV which became associated with the LDF was capable of reassociating with HDL, and vice versa. These findings suggest the possibility that, in LDF, apo A-IV exists in two pools, of which one is exchangeable while the other is independent of the redistribution system involving plasma or lymph lipoproteins.
The possibility that the isolated or radioiodinated apo A-IV preparations contained significant proportions of nonexchangeable material due to denaturation is unlikely for several reasons. First, the source ofthe apolipoprotein was lymph chylomicrons, and the peptide was immunoaffinity purified in contrast to other isolation procedures involving lengthy exposures to denaturing reagents. Second, this apo A-IV showed a similar isoprotein pattern by two-dimensional gel electrophoresis ( 11) to that obtained with delipidated whole lymph chylomicrons. Third, the labeled apo A-IV completely equilibrated between TRL and HDL. Fourth, the physical-chemical properties described above show no apparent evidence of denaturation after isolation or radioiodination of apo A-IV.
In a previous study, we showed that in fact apo A-IV does exist in LDF in a heterogeneous state in association with lipids and other apolipoproteins (1 1). Attempts to isolate free apo A-IV from LDF and lymph TRL by immunoabsorbance affinity chromatography were successful only with delipidated lymph TRL apolipoprotein. With LDF, even after delipidation using chloroform/methanol and ether, apo A-IV could not be separated from a complex involving apo A-IV and A-I and a protein of Mr 59,000. Lipid, especially cholesteryl ester, was also associated with this complex, suggesting that even within LDF apo A-IV exists in a lipoproteinlike species (1 1) . SDS disk gel electrophoresis of this complex from LDF showed a similar protein profile to that obtained from nondelipidated LDF after immunoabsorbance chromatography (1 1). These results strongly suggest that apo A-IV exists in LDF in some tight complex involving protein-protein or protein-lipid bonds that do not permit free exchange of apo A-IV.
In vivo studies. These studies reinforce the conclusions drawn from the incubations. However, in comparing the two sets of data it must be remembered that the design ofthe in vivo studies was closer to that of in vitro experiments 4-6 (Table II) than to that of experiments 1-3, since the injectates contained 1251I-apo A-IV that had been preequilibrated in vitro with the test lipoprotein or LDF fraction. As already discussed, such preincubation allows for lesser subsequent exchange than when free '251-apo A-IV is tested.
Nevertheless, each of the in vivo studies was consistent with the in vitro data in showing rapid exchange of 125I-apo A-IV among plasma apo A-IV containing fractions and the failure of isotopic equilibrium to occur between apo A-IV in HDL and in LDF. Indeed the higher "final" specific radioactivity for apo A-IV in HDL was similar in both the in vitro and in vivo experiments. It is therefore clear that only a minor fraction of apo A-IV in LDF is exchangeable with other apo A-IV in plasma. As indicated above, this is consistent with our previous observation (I 1) that apo A-IV exists in "minilipoprotein" form in more than one complex, with that in HDL differing from that in LDF.
In both the in vitro and in vivo experiments, the amount of 1251I-apo A-IV that became associated with HDL was disproportionately high in relation to its mass distribution. In the in vivo studies, most labeled apo A-IV remained with the HDL when HDL was reinjected (Fig. 5) ; less associated with HDL when LDF or TRL were reinjected. HDL therefore appears to have a particularly high affinity for at least one apo A-IV complex which, based on the evidence, has a far greater rate of metabolism than the less freely exchangeable apo A-IV complex that represents a major form in LDF. The apparently similar rates of removal of '251I-apo A-IV, after the initial equilibration period (of the exchangeable pool) within the TRL (VLDL), HDL, and LDF, probably reflects the metabolism of one common complex of apo A-IV.
These studies do not indicate whether both apo A-IV complexes in LDF participate in the rapid exchange with TRL and LDF or whether apo A-IV in one complex is more refractory to exchange than is the other complex. Possibly two complexes have different physiological functions. The exchangeable fraction may derive from triglyceride transport from the gut and is readily dissociated from lymph chylomicrons within plasma. This is consistent with several observations that apo A-IV is synthesized at least in part in the small intestine and becomes incorporated into lymph chylomicrons during the absorption of fat ( 12) . It is not clear why HDL should have such a high affinity for apo A-IV, other than this is not unique for this chylomicron peptide. However, in a previous study in the rat (3), we noted an even greater transfer of chylomicron '251I-apo A-IV to HDL, consistent with the relatively greater mass of apo A-IV in rat HDL. Furthermore, a proportion of LDF 125I-apo A-IV, derived initially from chylomicrons, transferred later to HDL, suggesting that in the rat there may be greater homogeneity of apo A-IV complexes between HDL and LDF than we have now observed in humans.
In addition to the clear involvement of apo A-IV in dietary triglyceride transport, there is increasing evidence that the metabolism of apo A-IV may be related to cholesterol metabolism. Delamatre and Roheim (8) recently found that dietary cholesterol led to redistribution of apo A-IV from HDL into the lipoproteinfree fraction in rats. Furthermore both lecithin cholesterol acyltransferase (9) and lipoprotein lipase (22) activity also appear to influence the distribution of apo A-IV, at least in the rat. It is also of interest that LCAT activity from human plasma can be moderately stimulated by apo A-IV (23) though only 25% as effectively as a corresponding amount of apo A-I.
Finally, the large pool of apo A-IV present in the fraction of plasma of d > 1.21 g/ml, which has now been shown to exist in discrete lipid-protein complexes (1 1), may have several metabolic functions. In recent studies in this laboratory (Fidge, N. H., and P. J. Nestel, unpublished observations), it was found that radiolabeled apo A-IV was able to transfer from the plasma into the lymph compartment of rats where it became associated with chylomicrons after fat feeding. This shows that apolipoproteins can move freely between lymph and plasma and transfer to chylomicrons after their assembly and secretion from enterocytes. One other possible explanation for the unusual distribution of apo A-IV is that the peptide may have other metabolic func-tions independent of fat transport. These possibilities await more detailed information 'about the tissue distribution of apo A-IV and those factors that regulate its cellular synthesis and removal within the body.
